BCCA Protocol Summary for Palliative Treatment of Patients with Recurrent Malignant Gliomas and Ependymoma Using Low Dose Etoposide

**Protocol Code**
CNETO

**Tumour Group**
Neuro-Oncology

**Contact Physician**
Dr. Brian Thiessen

**ELIGIBILITY**
1. Patients with malignant gliomas and ependyomas which failed nitrosourea and temozolomide-based regimen.
2. Normal bone marrow, hepatic and cardiac function.

**TESTS:**
- **Baseline:** CBC and differential, platelets, serum creatinine and AST, ALT, bilirubin
- **Prior to each cycle:** CBC and differential, platelets, creatinine
- **Neuroimaging** every 2-3 cycles

**PREMEDICATIONS**
- Antiemetic protocol for Low emetogenic chemotherapy (see protocol SCNAUSEA)
- Hydrocortisone and diphenhydramine for history of hypersensitivity to etoposide

**Treatment:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>etoposide</td>
<td>50 mg once daily x 21 days</td>
<td>PO</td>
</tr>
</tbody>
</table>

- Repeat every 28 days until progression or intolerance.
DOSE MODIFICATIONS:

1. For Hematology:

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets (x10^9/L)</th>
<th>Etoposide Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than 1.5 and greater than or equal to 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>less than 100</td>
<td>delay</td>
<td></td>
</tr>
<tr>
<td>1.0-1.5 and greater than or equal to 100</td>
<td>75%</td>
<td></td>
</tr>
<tr>
<td>less than 100</td>
<td>delay</td>
<td></td>
</tr>
<tr>
<td>less than 1.0 and greater than or equal to 100</td>
<td>delay</td>
<td></td>
</tr>
<tr>
<td>less than 100</td>
<td>delay</td>
<td></td>
</tr>
</tbody>
</table>

- For neutropenic fever, reconsider treatment plan.

2. For serum creatinine 1.5 times upper limit normal, review program.

3. Hepatic dysfunction: If AST/AST greater than 5 x ULN or bilirubin greater than 25 micromol/L, review program.

PRECAUTIONS:

1. Neutropenia: Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Brian Thiessen or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 Aug 2006

Date revised: 1 Mar 2017 (Reformatted with various clarifications)

REFERENCES